Journal: Nature cardiovascular research
Article Title: Trem2 promotes foamy macrophage lipid uptake and survival in atherosclerosis
doi: 10.1038/s44161-023-00354-3
Figure Lengend Snippet: a , WT and Trem2 −/− BV2s assessed for Trem2 expression by flow cytometry. WT ( b ) or Trem2 −/− ( c ) BV2 macrophages DEGs from bulk RNA-seq determined by Wald test with DESeq2. d , GSEA plot of cholesterol biosynthesis pathways. ES, enrichment score. e , Pathway analysis of RNA-seq data comparing WT and Trem2 −/− non-foamy BV2 cells. f , Pathway analysis of RNA-seq data comparing WT and Trem2 −/− foamy BV2 cells. e , f , Significant pathways determined using weighted Kolmogorov–Smirnov test. g , WT or Trem2 −/− cell supernatant assessed for cytotoxicity by LDH assay after 16 h ( n = 6 biological replicates per group). Foamy: 20 μg ml −1 cholesterol; foamy hi : 80 μg ml −1 cholesterol. Data are mean ± s.e.m. Two-tailed ANOVA, *** P < 0.001. h , DiI-oxLDL uptake for WT or Trem2 −/− non-foamy and foamy BV2 macrophages ( n = 6 for non-foamy WT and Trem2 −/− and n = 4 foamy WT and Trem2 −/− biological replicates). Data are mean ± s.e.m. Student’s t -test, *** P < 0.001. i , WT or Trem2 −/− non-foamy and foamy BV2 macrophage efferocytosis. Efferocytotic cells were determined by the percent of BV2s that were positive for CTV-labeled splenocytes ( n = 5 biological replicates per group). Data are mean ± s.e.m. Student’s t -test, ** P < 0.01 and **** P < 0.0001. j , WT or Trem2 −/− non-foamy and foamy BV2 macrophage sXBP1 expression. Tunicamycin was used as a positive control ( n = 6 biological replicates per group). FMO (fluorescence minus one) shows unstained control. Data are mean ± s.e.m. Two-tailed ANOVA, ** P < 0.01. k , WT or Trem2 −/− foamy BV2 macrophages (80 μg ml −1 cholesterol) plus 10 μM PBA. Cell supernatant was assessed for cytotoxicity by LDH assay after 16 h ( n = 6 biological replicates per group). Data are mean ± s.e.m. Two-tailed ANOVA, **** P < 0.0001. l , GSEA plot of cholesterol efflux pathways from RNA-seq. m , GSEA plot of NR1H2 and NR1H3 gene target pathways from RNA-seq. n , WT or Trem2 −/− foamy BV2 macrophages (80 μg ml −1 cholesterol) ± T0901317 percent cytotoxicity ( n = 5 biological replicates per group). Data are mean ± s.e.m. Two-tailed ANOVA, **** P < 0.0001. o , WT or Trem2 −/− foamy BV2 macrophages (80 μg ml −1 cholesterol) ± 10 μM T0901317, assessed for sXBP1 levels by flow cytometry. Tunicamycin was used as a positive control ( n = 5 biological replicates per group). Data are mean ± s.e.m. Two-tailed ANOVA, **** P < 0.0001. KO, knockout; NS, not significant.
Article Snippet: The following antibodies were used: Trem2 APC rat anti-mouse (clone 237920, R&D Systems); Trem2 FITC rat anti-mouse (clone 78.18, eBioscience); CD68 rat anti-mouse (clone FA-11, BioLegend); Ki67 rabbit anti-mouse (clone SP6, Abcam); CD45 BV480 rat anti-mouse (clone 30-F11, BioLegend); CD11b BV605 rat anti-mouse (clone M1/70, BioLegend); Ly6G BV785 rat anti-mouse (clone 1A8, BioLegend); Ly6C BV421 rat anti-mouse (clone HK1.4, BioLegend); CD115 PerCPCy5.5 rat anti-mouse (clone AFS98, BioLegend); TCRβ APC hamster anti-mouse (clone H57–597, BioLegend); CD19 FITC rat anti-mouse (clone 1D3, BioLegend); and sXBP1 AF647 rat anti-mouse (clone E9V3E, Cell Signaling Technology).
Techniques: Expressing, Flow Cytometry, RNA Sequencing, Lactate Dehydrogenase Assay, Two Tailed Test, Labeling, Positive Control, Fluorescence, Control, Knock-Out